ibudilast has been researched along with Chronic Illness in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "At 6 months after the start of ibudilast therapy, all patients reported the resolution of dizziness; of the 6 patients with depression at entry, all experienced significant improvement." | 7.74 | Effect of ibudilast on non-specific symptoms in patients with chronic cerebral ischemia. Analysis of cerebral blood flow. ( Harada, M; Inoue, N, 2008) |
| "At 6 months after the start of ibudilast therapy, all patients reported the resolution of dizziness; of the 6 patients with depression at entry, all experienced significant improvement." | 3.74 | Effect of ibudilast on non-specific symptoms in patients with chronic cerebral ischemia. Analysis of cerebral blood flow. ( Harada, M; Inoue, N, 2008) |
| "Ibudilast was generally well tolerated." | 2.73 | Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. ( Chang, E; Davidson, JB; Gibbons, JA; Gross, MI; He, L; Johnson, KW; Jones, D; Rolan, P; Sanftner, LM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, N | 1 |
| Harada, M | 1 |
| Rolan, P | 1 |
| Gibbons, JA | 1 |
| He, L | 1 |
| Chang, E | 1 |
| Jones, D | 1 |
| Gross, MI | 1 |
| Davidson, JB | 1 |
| Sanftner, LM | 1 |
| Johnson, KW | 1 |
| Wakita, H | 1 |
| Tomimoto, H | 1 |
| Akiguchi, I | 1 |
| Lin, JX | 1 |
| Ihara, M | 1 |
| Ohtani, R | 1 |
| Shibata, M | 1 |
| Katsumata, T | 1 |
| Katayama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ibudilast and Chronic Illness
| Article | Year |
|---|---|
[Treatment by medicine which improves cerebral circulation and metabolism].
Topics: Brain; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disease; Humans; Nicergoline; | 2006 |
1 trial available for ibudilast and Chronic Illness
| Article | Year |
|---|---|
Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.
Topics: Adolescent; Adult; Aged; Chronic Disease; Diabetic Neuropathies; Dose-Response Relationship, Drug; D | 2008 |
2 other studies available for ibudilast and Chronic Illness
| Article | Year |
|---|---|
Effect of ibudilast on non-specific symptoms in patients with chronic cerebral ischemia. Analysis of cerebral blood flow.
Topics: Aged; Brain Ischemia; Cerebrovascular Circulation; Chronic Disease; Depression; Dizziness; Female; F | 2008 |
Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat.
Topics: Administration, Oral; Animals; Brain Ischemia; Chronic Disease; Dose-Response Relationship, Drug; Im | 2003 |